ERBB2 and breast cancer: G Cancello et al. demonstrated an increased rate of local recurrence (HR = 4.53; 95 % CI: 1.56‒13.1) and distant metastases with decreased BCSS (HR = 3.22; 95 % CI +1.44‒7.18) and OS (HR = 2.87; 95 % CI: 0.05‒7.89) in HER2+ BC patients.31